Drexel University

Baruch S. Blumberg Institute

Thomas Jefferson University

United Therapeutics Corporation

Other

G.d. Searle & Company

Oxford University Innovation Ltd

Arbutus Biopharma Corporation

Institute for Hepatitis and Virus Research

University of Illinois

Enantigen Therapeutics, Inc.

Monsanto Company

Timothy Michael Block

Xiaodong Xu

Anand Mehta

Ju-Tao Guo

Jinhong Chang

Raymond A Dwek

Mary Ann Comunale

Andrea Cuconati

Gary S Jacob

Yanming Du

Hong Ye

Terry D Butters

Frances M Platt

Nicole Zitzmann

Tong Xiao

William Alvin Kinney

Donald H Picker

Harold R Almond

George W J Fleet

Baruch S Blumberg

Fang Guo

Sandra Carrouee

David Durantel

Richard A Mueller

Richard A Partis

Martin L Bryant

Huagang Lu

Haitao Guo

Simon David Peter Baugh

Ying-Hsiu Su

Frank H Michaels

Dawei Cai

Xuanyong Lu

Mark Feitelson

Baohua Gu

Robert M Moriarty

Mahendra N Deshpande

Robert H Grafstrom

Mengjun Wang

Benjamin Song

Janet Song

Rajendra C Shah

Patrick Robert Romano

Simon David Baugh

Frank Michaels

Provided are methods, assays, and kits for detecting hepatocellular carcinoma, as well as methods for stratifying subjects among higher and lower risk categories for having hepatocellular carcinoma, and methods of treating and managing treatment of subjects that are suspected or at risk of having hepatocellular carcinoma. Although previous work has attempted to address the need for a highly sensitive, early predictor of hepatocellular carcinoma by assessment of one or more biological factors, none have approached the degree of sensitivity that is required for clinically relevant determination of whether a subject, especially a non-symptomatic subject, has that condition. The present inventors have discovered that certain combinations of factors fulfill this need by conferring a high level of accuracy that was not previously attainable.

Early detection of hepatocellular carcinoma

Methods for diagnosing pathology of the liver in a subject suspected of having such pathology are disclosed. The methods comprise quantifiably detecting lectin binding on proteins in biological fluids, and comparing the detected lectin binding with reference values for the binding of lectin of such proteins in healthy or disease states.

Diagnosis of liver pathology through assessment of protein glycosylation

Described herein are alkylated imino sugars derivatives having a disease-modifying action in the treatment of diseases associated with glucosidase activity that include viral hemorrhagic fevers and other enveloped viruses, and any other diseases involving glucosidase activity.

2,3-diacylated, 2- and 3-mono-acylated alkylated imino sugars exhibiting glucosidase inhibition and their method of use

Pharmaceutical compositions of the invention comprise alkylated imino sugars derivatives having a disease-modifying action in the treatment of diseases associated with glucosidase activity that include Viral hemorrhagic fevers, and any other diseases involving glucosidase activity.

Alkylated imino sugars exhibiting glucosidase inhibition and their method of use

Methods for diagnosing pathology of the liver in subject suspected of having such pathology by measuring the glycosylation of anti-gal IgG in various biological fluids of the subject.

Diagnosis of liver pathology through assessment of anti-gal IgG glycosylation

The present invention provides small molecule inhibitors of hepatitis B virus (HBV) covalently closed circular (ccc) DNA, which are useful as therapeutics in the management of chronic HBV. The compounds of the invention achieve epigenetic modification of the cccDNA, histone modification and histone deacetylase activity inhibition, thus modulating HBV cccDNA. The present invention further provides methods for modulating HBV cccDNA, for treating or preventing HBV in a subject, and for modulating cccDNA transcription of hepatitis B in a subject.

Modulation of hepatitis B virus cccDNA transcription

Pharmaceutical compositions of the invention comprise substituted aminothiazoles derivatives having a disease-modifying action in the treatment of diseases associated with unregulated cell growth that include hepatocellular carcinoma, and infection with a hepatitis virus.

Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication

Methods for diagnosing pathology of the liver in a subject suspected of having such pathology are disclosed. The methods comprise quantifiably detecting glycosylation, and more specifically fucosylation, on proteins in biological fluids, and comparing the detected glycosylation with reference values for the glycosylation of such proteins in healthy or disease states.

Provided herein are methods of treating a subject having hepatitis B viral (HBV) infection. More specifically, disclosed herein are methods of stimulating the innate cytokine response in macrophages, dendritic cells and/or liver non-parenchymal cells with small molecular agonists of STING to suppress HBV replication in hepatocytes. The methods are especially suitable for use in the treatment of chronic HBV infections. Also disclosed herein are methods of identifying compounds useful in the treatment of HBV infection.

Use of sting agonists to treat chronic hepatitis B virus infection

The present invention provides novel compounds of formula (I) and methods of use thereof. In certain embodiments, the compounds of the invention are useful as nucleocapsid assembly inhibitors. In other embodiments, the compounds of the invention are useful as pregenomic RNA encapsidation inhibitors of Hepatitis B virus (HBV). In yet other embodiments, the compounds of the invention are useful for the treatment of viral infection, including HBV and related viral infections.

Antiviral agents against HBV infection

The present invention provides sulfamoylbenzamide derivatives, and pharmaceutical compositions thereof. In certain embodiments, the compounds and pharmaceutical compositions of the invention inhibit pregenomic RNA encapsidation. In other embodiments, the compounds and pharmaceutical compositions of the invention are useful for treating Hepatitis B virus (HBV) infection.

Sulfamoylbenzamide derivatives as antiviral agents against HBV infection

Pharmaceutical compositions of the invention comprise covalently closed circular DNA formation inhibitors having a disease-modifying action in the treatment of diseases associated with the formation of covalently closed circular DNA that include hepatitis B infection, and any disease involving formation of covalently closed circular DNA.

Inhibitors of hepatitis B virus covalently closed circular DNA formation and their method of use

The invention includes methods of treating a subject having hepatitis B viral (HBV) infection. In certain embodiments, the method of the invention comprises stimulating the innate cytokine response in macrophages, dendritic cells and/or liver non-parenchymal cells with small molecular STING agonists, thus suppressing HBV replication in hepatocytes. In other embodiments, the method of the invention can be used to treat chronic HBV infections. The invention further provides methods of identifying compounds useful in treating HBV infection in a subject.

Use of sting agonists to treat hepatitis B virus infection

Modulation of hepatitis B virus CCCDNA transcription

Pharmaceutical compositions of the invention comprise triazolopyrimidines useful for the treatment of hepatitis virus in a patient.

Inhibitors of secretion of hepatitis B virus antigens

Growing community of inventors

Doylestown, PA, United States of America

Timothy Michael Block